Eli Lilly’s Manjaro gains from Novo Nordisk’s Wegovy in the UK By Investing.com
A significant shift is taking place in the UK weight loss drug market as Eli Lilly’s (NYSE: ) Manjaro begins to overtake Novo Nordisk (NYSE: )’s Wegovy among British customers paying for obesity treatment. Online pharmacy reports show a growing preference for Manjaro over its competitor, reflecting Eli Lilly’s progress against the European pharmaceutical company.
Manjaro has become very popular with consumers due to its high performance in clinical trials conducted before drug approval. The data revealed that while Wegovy enabled patients to lose an average of 15% of their body weight, Manjaro resulted in a weight loss of around 23%, a significant difference in results.
Despite its growing popularity, Manjaro is not yet available through the UK’s National Health Service (NHS). However, speculation suggests it could become accessible through the NHS next year. In contrast, Wegovy has limited availability through the NHS, restricted to specialist obesity clinics and certain relevant conditions.
Eli Lilly launched Manjaro in the UK in February, marking one of the first markets outside the United States where the drug was available. Wegovy has been on the UK market since 2023, in a country where almost two-thirds of adults are considered overweight or obese, indicating a significant customer base for these obesity treatments.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
